Aloe vera polysaccharide nanodrug (LDG@AMI) repairs intestinal barrier in microfluidic enteritis chip model
Background
Inflammatory bowel diseases like enteritis are characterized by chronic inflammation and impaired intestinal barrier function, leading to increased permeability and symptom exacerbation. Current treatments, such as 5-aminosalicylic acid (5-ASA), often lack targeted delivery and sustained release, limiting their efficacy and increasing systemic side effects. Developing nanodrugs that can precisely respond to the intestinal microenvironment and enhance barrier repair is a critical gap, particularly when evaluated in physiologically relevant in vitro models that mimic the complex intestinal architecture.
Study Design
Researchers constructed a microfluidic enteritis chip model to simulate the intestinal microenvironment. They synthesized LDG@AMI, an Aloe vera polysaccharide copolymer nanodrug loaded with 5-aminosalicylic acid (5-AMI). The chip model was induced with sodium dextran sulfate (DSS) to create an enteritis-like state. Cell viability and expression of intestinal barrier protein ZO-1 and intestinal mucosa protein WGA were measured via fluorescence microscopy. Nanodrug characteristics (morphology, size, composition, swelling, release) were assessed using TEM, nanoparticle size analyzer, FT-IR, and UV-Vis spectroscopy. Inflammatory factors (TNF-α, IL-6, IL-1β) were quantified by ELISA.
Results
The constructed enteritis chip model successfully mimicked intestinal inflammation, showing increased permeability, elevated HIF-1α expression, and significantly declined ZO-1 and WGA levels after DSS treatment. The synthesized LDG@AMI nanodrug exhibited a particle size of about 80 nm, demonstrated a high swelling rate, and possessed sustained release properties, accurately responding to the intestinal microenvironment. Importantly, the nanodrug showed superior barrier repair capabilities:
LDG@AMI-treated enteritis chips displayed higher expression levels of ZO-1 and WGA compared to the 5-AMI-treated group, indicating excellent barrier repair. While inflammatory factors (
TNF-α,IL-6,IL-1β) were quantified, specific data on their modulation by LDG@AMI were not detailed in the abstract.
Key Findings
- A microfluidic enteritis chip model was successfully constructed, exhibiting increased permeability and altered protein expression post-DSS treatment.
- The LDG@AMI nanodrug had a particle size of approximately 80 nm and demonstrated sustained release properties.
- LDG@AMI treatment led to higher expression levels of intestinal barrier protein ZO-1 compared to 5-AMI alone.
- LDG@AMI treatment resulted in higher expression levels of intestinal mucosa protein WGA compared to 5-AMI alone.
Why It Matters
This study introduces a promising nanodrug, LDG@AMI, that effectively restores intestinal barrier integrity in an in vitro enteritis model, suggesting a potential new therapeutic avenue for inflammatory bowel conditions. The use of a microfluidic enteritis chip represents a significant step forward in drug screening, offering a more physiologically relevant platform than traditional 2D cell cultures. This approach could lead to more targeted and efficient drug delivery systems for intestinal inflammation, potentially reducing systemic side effects and improving patient outcomes. Further in vivo studies are needed to validate these findings and move towards clinical translation, but the in vitro model provides a robust foundation for future development.
enteritis
nanodrug
microfluidics
intestinal-barrier
5-aminosalicylic-acid
aloe-vera